
Oncology NEWS International
- Oncology NEWS International Vol 10 No 9
- Volume 10
- Issue 9
‘Art of the Brain’ Raises Funds for Brain Cancer Research at UCLA
LOS ANGELES-Diagnosed with a life-threatening brain tumor 8 years ago, Mario del Valle chose not to be physically defeated. His artist mother, Pilar del Valle, helped inspire him to learn to use his left hand. Mr. del Valle, born in Colombia and now living in Northridge, California, overcame vision and other obstacles to produce watercolors such as the two shown above. Mr. del Valle is a participant in the UCLA Neuro-Oncology Program’s Art of the Brain, which encourages brain cancer patients and their caregivers to use creativity to regain self-worth and personal power. Timothy Cloughsey, MD, is director of the UCLA Neuro-Oncology Program
LOS ANGELESDiagnosed with a life-threatening brain tumor 8 years ago, Mario del Valle chose not to be physically defeated. His artist mother, Pilar del Valle, helped inspire him to learn to use his left hand. Mr. del Valle, born in Colombia and now living in Northridge, California, overcame vision and other obstacles to produce watercolors such as the two shown above. Mr. del Valle is a participant in the UCLA Neuro-Oncology Program’s Art of the Brain, which encourages brain cancer patients and their caregivers to use creativity to regain self-worth and personal power. Timothy Cloughsey, MD, is director of the UCLA Neuro-Oncology Program
Art of the Brain was founded by brain cancer survivor Judi Kaufman to raise funds for advanced brain cancer research. Last year, Art of the Brain sponsored a festival that featured art from brain cancer patients and their caregivers alongside the work of world-renowned artists. This year’s event, Music from the Heart (October 7), will showcase brain cancer patients in musical performances.
Articles in this issue
almost 25 years ago
Avon Launches ‘Kiss Goodbye to Breast Cancer’ Campaignalmost 25 years ago
Occult Tumor Cells in Marrow Predict Breast Cancer Survivalalmost 25 years ago
No Long-Term Advantage for Complete Response to Neoadjuvant Chemo/RTalmost 25 years ago
New Agents Tested with 5-FU in Rectal Canceralmost 25 years ago
Anticonvulsants Can Alter Irinotecan Metabolismalmost 25 years ago
Thalidomide Appears Effective in Early-Stage Myelomaalmost 25 years ago
Irinotecan Plus Cisplatin Used as First-Line Treatment of Ovarian Cancersalmost 25 years ago
New ‘Goals for Pain Relief’ Scale Proves Reliable in Pilot Studyalmost 25 years ago
GVAX Autologous Vaccine Shows Activity in Lung Cancer

















































































